Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Nucleoporin Nup155 is part of the p53 network in liver cancer.

Holzer K, Ori A, Cooke A, Dauch D, Drucker E, Riemenschneider P, Andres-Pons A, DiGuilio AL, Mackmull MT, Baßler J, Roessler S, Breuhahn K, Zender L, Glavy JS, Dombrowski F, Hurt E, Schirmacher P, Beck M, Singer S.

Nat Commun. 2019 May 14;10(1):2147. doi: 10.1038/s41467-019-10133-z.

2.

Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans.

Zhivagui M, Ng AWT, Ardin M, Churchwell MI, Pandey M, Renard C, Villar S, Cahais V, Robitaille A, Bouaoun L, Heguy A, Guyton KZ, Stampfer MR, McKay J, Hollstein M, Olivier M, Rozen SG, Beland FA, Korenjak M, Zavadil J.

Genome Res. 2019 Apr;29(4):521-531. doi: 10.1101/gr.242453.118. Epub 2019 Mar 7.

3.

Non-Thermal Plasma, as a New Physicochemical Source, to Induce Redox Imbalance and Subsequent Cell Death in Liver Cancer Cell Lines.

Smolková B, Lunova M, Lynnyk A, Uzhytchak M, Churpita O, Jirsa M, Kubinová Š, Lunov O, Dejneka A.

Cell Physiol Biochem. 2019;52(1):119-140. doi: 10.33594/000000009. Epub 2019 Feb 18.

4.

The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases.

Balacescu O, Sur D, Cainap C, Visan S, Cruceriu D, Manzat-Saplacan R, Muresan MS, Balacescu L, Lisencu C, Irimie A.

Int J Mol Sci. 2018 Nov 22;19(12). pii: E3711. doi: 10.3390/ijms19123711. Review.

5.

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin W, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK.

Clin Cancer Res. 2019 Apr 1;25(7):2116-2126. doi: 10.1158/1078-0432.CCR-18-2293. Epub 2018 Oct 29.

PMID:
30373752
6.

Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53.

Di Leo L, Vegliante R, Ciccarone F, Salvatori I, Scimeca M, Bonanno E, Sagnotta A, Grazi GL, Aquilano K, Ciriolo MR.

Oncogene. 2019 Mar;38(11):1860-1875. doi: 10.1038/s41388-018-0545-0. Epub 2018 Oct 26.

PMID:
30367149
7.

Modeling hepatitis C virus protein and p53 interactions in hepatocytes: Implications for carcinogenesis.

Poole MI, Sorribes I, Jain HV.

Math Biosci. 2018 Dec;306:186-196. doi: 10.1016/j.mbs.2018.10.003. Epub 2018 Oct 10.

PMID:
30312632
8.

Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation.

Lou W, Chen J, Ding B, Chen D, Zheng H, Jiang D, Xu L, Bao C, Cao G, Fan W.

J Transl Med. 2018 Sep 29;16(1):266. doi: 10.1186/s12967-018-1639-8.

9.

Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.

Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, Pawlik TM.

Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8. Review.

PMID:
29937183
10.

Germline Duplication of SNORA18L5 Increases Risk for HBV-related Hepatocellular Carcinoma by Altering Localization of Ribosomal Proteins and Decreasing Levels of p53.

Cao P, Yang A, Wang R, Xia X, Zhai Y, Li Y, Yang F, Cui Y, Xie W, Liu Y, Liu T, Jia W, Jiang Z, Li Z, Han Y, Gao C, Song Q, Xie B, Zhang L, Zhang H, Zhang J, Shen X, Yuan Y, Yu F, Wang Y, Xu J, Ma Y, Mo Z, Yu W, He F, Zhou G.

Gastroenterology. 2018 Aug;155(2):542-556. doi: 10.1053/j.gastro.2018.04.020. Epub 2018 Apr 24.

PMID:
29702115
11.

Targeting PRPK Function Blocks Colon Cancer Metastasis.

Zykova T, Zhu F, Wang L, Li H, Lim DY, Yao K, Roh E, Yoon SP, Kim HG, Bae KB, Wen W, Shin SH, Nadas J, Li Y, Ma W, Bode AM, Dong Z.

Mol Cancer Ther. 2018 May;17(5):1101-1113. doi: 10.1158/1535-7163.MCT-17-0628. Epub 2018 Feb 26.

12.

Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.

Liao P, Zeng SX, Zhou X, Chen T, Zhou F, Cao B, Jung JH, Del Sal G, Luo S, Lu H.

Mol Cell. 2017 Dec 21;68(6):1134-1146.e6. doi: 10.1016/j.molcel.2017.11.006. Epub 2017 Dec 7.

13.

Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer.

Joung JG, Oh BY, Hong HK, Al-Khalidi H, Al-Alem F, Lee HO, Bae JS, Kim J, Cha HU, Alotaibi M, Cho YB, Hassanain M, Park WY, Lee WY.

Clin Cancer Res. 2017 Dec 1;23(23):7209-7216. doi: 10.1158/1078-0432.CCR-17-0306. Epub 2017 Sep 22.

14.

MCUR1-Mediated Mitochondrial Calcium Signaling Facilitates Cell Survival of Hepatocellular Carcinoma via Reactive Oxygen Species-Dependent P53 Degradation.

Ren T, Wang J, Zhang H, Yuan P, Zhu J, Wu Y, Huang Q, Guo X, Zhang J, Ji L, Li J, Zhang H, Yang H, Xing J.

Antioxid Redox Signal. 2018 Apr 20;28(12):1120-1136. doi: 10.1089/ars.2017.6990. Epub 2017 Nov 1.

PMID:
28938844
15.

P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.

Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS.

Sci Rep. 2017 Aug 29;7(1):9711. doi: 10.1038/s41598-017-09859-x.

16.
17.

Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.

Nakayama M, Sakai E, Echizen K, Yamada Y, Oshima H, Han TS, Ohki R, Fujii S, Ochiai A, Robine S, Voon DC, Tanaka T, Taketo MM, Oshima M.

Oncogene. 2017 Oct 19;36(42):5885-5896. doi: 10.1038/onc.2017.194. Epub 2017 Jun 19.

18.

Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells.

Li H, Rokavec M, Jiang L, Horst D, Hermeking H.

Gastroenterology. 2017 Aug;153(2):505-520. doi: 10.1053/j.gastro.2017.04.017. Epub 2017 Apr 20.

PMID:
28435028
19.

Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.

Mao R, Liu J, Liu G, Jin S, Xue Q, Ma L, Fu Y, Zhao N, Xing J, Li L, Qiu Y, Lin B.

Oncotarget. 2017 Apr 18;8(16):26185-26199. doi: 10.18632/oncotarget.15428.

20.

Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.

Zhang W, He H, Zang M, Wu Q, Zhao H, Lu LL, Ma P, Zheng H, Wang N, Zhang Y, He S, Chen X, Wu Z, Wang X, Cai J, Liu Z, Sun Z, Zeng YX, Qu C, Jiao Y.

Gastroenterology. 2017 Jul;153(1):249-262.e2. doi: 10.1053/j.gastro.2017.03.024. Epub 2017 Mar 29.

PMID:
28363643

Supplemental Content

Loading ...
Support Center